Helixmith Co. LTD. is a biotechnology company located in Seoul, South Korea with US presence in San Diego.

Helixmith’s lead gene is Engensis (VM202), currently in phase III diabetic peripheral neuropathy (DPN) in the US.

In AAV gene therapy, the company has a number of early stage products targeting neuromuscular diseases such as ALS and multiple sclerosis.

The company has unique experience in areas including natural medicine, health functional food and cosmetic products using botanical sources.

A single injection of Helixmith’s proprietary plasmid DNA product expresses the HGF gene at levels 30-40 times higher than conventional plasmid DNA and provides sustained gene expression in mouse models for 2 weeks, with peak protein expression at Day 7 and a gradual decrease over the next week To date, more than 500 patients have been treated with Engensis across ten clinical trials in six different diseases and conditions.

Data from previous clinical studies suggest that Engensis is well tolerated and has the potential to provide durable analgesic and/or symptomatic relief in a variety of disease settings.

Beyond potentially alleviating pain, Engensis is designed to target the underlying causes of neuropathy through its predicted angiogenic and neuroregenerative properties.

According to its website, the company is involved in the following clinical trials: Helixmith currently has two target indications under its phytotherapeutics pipeline: PG201 (Osteoarthritis), and HX204 (Inflammatory bowel disease).

It is being sold under the brand name “LAYLA Tab” and has been generating a domestic annual revenue of 20 billion KRW since it has been licensed out to PMG Pharma.